Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

Fraiche, Ariane M.; Wang, Andrew

doi:10.1007/s11886-016-0751-8

Cited by 8 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a validation study of 1629 patients with HCM in the United States, the risk of SCD calculated by the ESC risk score was significantly lower than the actual event rate. Only 11% of 35 patients who had an SCD event were considered high-risk, which indicated that ICD was recommended, whereas 60% of the patients who experienced a clinical SCD event were low-risk, and ICD was not recommended [ 44 , 45 ]. On the other hand, Nakagawa et al validated the Risk-SCD model in 370 Japanese patients with HCM and reported the supportive results, in particular for those with LVEF ≥ 50% [ 46 ].…”

Section: Risk Of Sudden Cardiac Deathmentioning

confidence: 99%

Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging

Kitai

Xanthopoulos

Nakagawa

et al. 2022

JCDD

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart disease with an estimated prevalence of 0.2–0.5%. Although the prognosis of HCM is relatively good, with an annual general mortality of ~0.7%, some patients have an increased risk of sudden death, or of developing severe heart failure requiring heart transplantation or left ventricular (LV) assist device therapy. Therefore, earlier diagnosis and proper identification of high-risk patients may reduce disease-related morbidity/mortality by promoting timely treatment. Echocardiography is the primary imaging modality for patients with suspected HCM; it plays central roles in differential diagnosis from other causes of LV hypertrophy and in evaluating morphology, hemodynamic disturbances, LV function, and associated valvular disease. Echocardiography is also an essential tool for the continuous clinical management of patients with confirmed HCM. Other imaging modalities, such as cardiac computed tomography (CT) and cardiac magnetic resonance imaging (MRI), can supplement echocardiography in identifying high-risk as well as milder HCM phenotypes. The role of such multimodality imaging has been steadily expanding along with recent advancements in surgical techniques and minimally invasive procedures, and the emergence of novel pharmacotherapies directly targeting pathogenic molecules such as myosin inhibitors. Here we review essential knowledge surrounding HCM with a specific focus on structural and functional abnormalities assessed by imaging modalities, leading to treatment strategies.

show abstract

Section: Risk Of Sudden Cardiac Deathmentioning

confidence: 99%

Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging

Kitai

Xanthopoulos

Nakagawa

et al. 2022

JCDD

View full text Add to dashboard Cite

show abstract

“…2 É uma realidade em crescimento desde há três décadas em Portugal e no mundo, tanto nos cuidados de saúde primários como hospitalares. [2][3][4][5][6][7] A teleconsulta apresenta potenciais benefícios para os utentes, nomeadamente o aumento da acessibilidade aos serviços de saúde, sobretudo para os que habitam fora dos centros urbanos, 4,8 conveniência para o utente, redução dos custos de deslocação e poupança de tempo, que poderá ter particular importância para utentes ou cuidadores informais profissionalmente ativos. [8][9][10][11] Apresenta também benefícios para os sistemas de saúde e permite fazer face a catástrofes e emergências de saúde pública.…”

Section: Introductionunclassified

Consulta Não Presencial no Serviço Nacional de Saúde Português Durante a Pandemia de COVID-19: Estudo da Opinião dos Médicos e Implicações para o Futuro

et al. 2022

View full text Add to dashboard Cite

Introduction: The COVID-19 pandemic led to the reorganization of healthcare services and teleconsultation emerged as a solution to facilitate patient appointments. The aim of this study was to characterize, from a physician perspective, the teleconsultations carried out in the Portuguese National Health Service (SNS) during the first phase of the pandemic and to identify factors that influence the experience of the teleconsultation.Material and Methods: A cross-sectional analytical study was conducted based on an online survey, between July-September 2020, aimed at SNS doctors. Data on demographics, practice, attitudes and perceptions associated with the teleconsultation was collected. The adjusted prevalence ratio (aPR) was calculated to identify demographic factors and determinants of teleconsultation associated with satisfaction, use of video calls and greater motivation to carry out teleconsultations in the future.Results: 2225 valid responses were obtained. Teleconsultation was carried out by 93.8% of participants in this period, 99.0% used the telephone as a form of communication and only 8.0% used a video call. A high degree of satisfaction with the teleconsultation was significantly associated with perceiving the teleconsultation as providing care with equivalent quality to a face-to-face consultation (aPR = 1.472) and being motivated to do teleconsultation after the pandemic (aPR = 4.081). Reporting clinical (aPR = 0.763) or technical difficulties (aPR = 0.666) was negatively associated with satisfaction). 70.4% of doctors would like to continue doing follow-up teleconsultations and 53.3% consider that video call technologies should always or often be used during teleconsultations.Conclusion: Teleconsultation seems to have potential to to become a common practice in the future. However, it is important to address clinical, technical, organizational, and legal questions and, above all, to ensure that it is a safe and valuable practice for patients.

show abstract

Risk stratification in hypertrophic cardiomyopathy

Marrakchi

Kammoun

Bennour

et al. 2018

Herz

View full text Add to dashboard Cite

Sudden cardiac death (SCD) is the most devastating complication of hypertrophic cardiomyopathy (HCM). The greatest challenge in the management of HCM is identifying those at increased risk, since an implantable cardioverter-defibrillator (ICD) is a potentially life-saving therapy. We sought to summarize the available data on SCD in HCM and provide a clinical perspective on the current differing and somewhat conflicting data on risk stratification, with balanced guidance regarding rational clinical decision-making. Additionally, we sought to determine the status of the current implementation of guidelines compiled by HCM experts worldwide. The HCM Risk-SCD model helps improve the risk stratification of HCM patients for primary prevention of SCD by calculating an individual risk estimate that contributes to the clinical decision-making process. Improved risk stratification is important for decision-making before ICD implantation for the primary prevention of SCD.

show abstract

Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

Cited by 8 publications

References 37 publications

Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging

Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging

Consulta Não Presencial no Serviço Nacional de Saúde Português Durante a Pandemia de COVID-19: Estudo da Opinião dos Médicos e Implicações para o Futuro

Risk stratification in hypertrophic cardiomyopathy

Contact Info

Product

Resources

About